Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24861769 | 0.84 | CYP1A2 (0.50) | CYP1A2CYP2C19CYP2C9SMN1; SMN2LMNA | |
| SCHEMBL3637019 | 0.82 | CYP1A2 (1.00) | CYP1A2CYP2C19CYP2C9SMN1; SMN2LMNA | |
| SCHEMBL24162675 | 0.82 | CYP1A2 (0.73) | CYP1A2CYP2C19CYP2C9SMN1; SMN2LMNA | |
| SCHEMBL9672301 | 0.81 | SMN1; SMN2 (0.74) | CYP1A2CYP2C19CYP2C9SMN1; SMN2LMNA | |
| SCHEMBL26416648 | 0.79 | KDM4E (0.58) | CYP1A2CYP2C19CYP2C9LMNAPTGER4 | |
| SCHEMBL876603 | 0.75 | SMN1; SMN2 (0.73) | CYP1A2CYP2C19CYP2C9SMN1; SMN2LMNA | |
| SCHEMBL9673792 | 0.74 | SMN1; SMN2 (0.76) | CYP1A2CYP2C19CYP2C9SMN1; SMN2LMNA | |
| SCHEMBL24861830 | 0.74 | CYP1A2 (0.47) | CYP1A2CYP2C19CYP2C9SMN1; SMN2LMNA | |
| SCHEMBL9673128 | 0.73 | SMN1; SMN2 (0.74) | CYP1A2CYP2C19CYP2C9SMN1; SMN2LMNA | |
| SCHEMBL2071589 | 0.73 | SMN1; SMN2 (1.00) | CYP1A2CYP2C19CYP2C9SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230125494-A1 | SYNTHESIS OF NOVEL EP4 ANTAGONIST AND USE IN CANCER AND INFLAMMATION | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230125494-A1 | SYNTHESIS OF NOVEL EP4 ANTAGONIST AND USE IN CANCER AND INFLAMMATION | PTGER4, PTGER3, PTGER2 | CYP1A2 395/4885CYP2C19 948/4885CYP2C9 875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.